Alpine Immune Sciences, Inc. announced the appointment of Pamela Holland, Ph.D., as Senior Vice President, Research. Dr. Holland is an experienced cancer biologist with a proven track record of successfully discovering and progressing multiple pre-clinical therapeutics into clinical development. Most recently, Dr. Holland served as Vice President, Cancer Biology at Surface Oncology, overseeing biology and immunology research. During her tenure she played key roles in developing the Surface pipeline, driving multiple pre-clinical programs into Phase 1, as well as the establishment of an early strategic partnership with Novartis and more recently with GSK. Prior to joining Surface, Dr. Holland held roles of increasing responsibility in oncology research at Amgen, working extensively on TNF-receptor superfamily members, including death-receptor agonists. Members of her team were instrumental in the development of multiple discovery programs for cancer immunotherapy. Alpine Immune Sciences also announced that Remy Durand, Ph.D., currently Senior Vice President of Business Development and Corporate Strategy, has been promoted to Chief Business Officer. Dr. Durand joined Alpine Immune Sciences in 2018 to help lead the company’s corporate strategy and business development efforts. During his tenure, he has played a leading role in building the company’s partnerships with AbbVie and Adaptimmune, and has represented the company at investor meetings and conferences.